Glp-1s Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:22
Sep 15
Sep 15
Obesity/GLP-1 is clearest DTC proof point
Obesity/GLP-1 drugs are the clearest proof point that the DTC cash-pay model is viable. Only about half of the US employer coverage base covers obesity medications, so the other half faces a coverage gap and seeks alternative channels. This category drives roughly half of the $26B peak US DTC opportunity.
HIGH
00:23
Feb 06
Feb 06
Cheaper weight-loss pills drive GLP-1 adoption.
New weight-loss pills are even less expensive than shots, and with TrumpRx discounts expanding access, Dr. Oz projects America will lose about 100 million pounds this year, signaling strong adoption of GLP-1 weight-loss drugs.
MED
About Glp-1s Investor Commentary
Across the available history and selected sources, Buzzberg tracks Glp-1s across 2 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: Terence Flynn, Mehmet Oz.